TY  - JOUR 
AU  - Phan, D.B.
AU  - Jourdain, H.
AU  - González-Quesada, A.
AU  - Zureik, M.
AU  - Rivera-Díaz, R.
AU  - Sahuquillo-Torralba, A.
AU  - Descalzo-Gallego, M.A.
AU  - Lunt, M.
AU  - García Doval, José Ignacio
AU  - Sbidian, E.
AU  - Warren, R.B.
AU  - Yiu, Z.Z.N.
PY  - 2023
SN  - 2044-6055
UR  - http://hdl.handle.net/20.500.11940/21370
AB  - INTRODUCTION: Psoriasis is a chronic inflammatory skin disease. Adalimumab is an effective but previously expensive biological treatment for psoriasis. The introduction of biosimilars following the patent expiry of the originator adalimumab Humira has...
LA  - eng
KW  - Humans
KW  - Adalimumab
KW  - Biosimilar Pharmaceuticals
KW  - Cohort Studies
KW  - Psoriasis
KW  - Dermatitis
KW  - Treatment Outcome
TI  - Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study
DO  - 10.1136/bmjopen-2023-075197
T2  - BMJ open
M2  - e075197
KW  - AS Vigo
KW  - CHUVI
VL  - 13
ER  -